Related Experiment Video
Updated: Apr 21, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct
Brian G Blair1, Xinyan Wu, Muhammad Saddiq Zahari
1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract:
The PIK3CA gene encodes for the p110 alpha isoform of PI3 kinase and is one of the most frequently mutated oncogenes in human cancers. However, the mechanisms by which PIK3CA mutations activate cell signaling are not fully understood. Here we used a phosphoproteomic approach to compare differential phosphorylation patterns between human breast epithelial cells and two isogenic somatic cell knock in derivatives, each harboring a distinct PIK3CA mutation. We demonstrated differential phosphorylation patterns between isogenic cell lines containing a PIK3CA helical domain mutation (E545K) compared to cells with a PIK3CA kinase domain mutation (H1047R). In particular, the receptor tyrosine kinase, HER3, showed increased phosphorylation at tyrosine 1328 in H1047R cells versus E545K cells. Genetic studies using shRNA demonstrated that H1047R cells have a profound decrease in growth factor independent proliferation upon HER3 knock down, but this effect was attenuated in E545K cells. In addition, HER3 knock down led to reductions in both PI3 kinase and MAP kinase pathway activation in H1047R cells, but in E545K cells only PI3 kinase pathway diminution was observed. These studies demonstrate the power of using paired isogenic cell lines for proteomic analysis to gain new insights into oncogenic signal transduction pathways.
Insights
The PIK3CA gene mutations activate cancer signaling pathways differently. Phosphoproteomics revealed distinct HER3 phosphorylation and pathway activation between PIK3CA helical (E545K) and kinase (H1047R) domain mutations.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- The PIK3CA gene is frequently mutated in human cancers.
- Mechanisms of PIK3CA-driven oncogenesis are not fully understood.
- PIK3CA encodes the p110 alpha subunit of PI3-kinase.
Purpose of the Study:
- To investigate differential signaling activation by distinct PIK3CA mutations.
- To compare phosphoproteomic profiles of isogenic cells with PIK3CA mutations.
Main Methods:
- Phosphoproteomic analysis of isogenic human breast epithelial cell lines.
- Comparison of cells with PIK3CA helical domain (E545K) vs. kinase domain (H1047R) mutations.
- RNA interference (shRNA) studies to assess HER3 function.
Main Results:
- Distinct phosphorylation patterns were observed between E545K and H1047R PIK3CA mutant cells.
- HER3 phosphorylation at Y1328 was higher in H1047R cells.
- HER3 knockdown significantly impaired proliferation and PI3K/MAPK signaling in H1047R cells, but only PI3K signaling in E545K cells.
Conclusions:
- PIK3CA mutations differentially impact cell signaling pathways.
- HER3 plays a critical role in mediating the oncogenic effects of the H1047R mutation.
- Isogenic cell line models are powerful tools for dissecting cancer signaling.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

